Tumor Cell Mitotic Machinery (None)

The tumor cell mitotic machinery refers to the complex network of proteins and structures responsible for orchestrating mitosis—the process by which a cell divides its duplicated genome into two daughter cells. In cancer, this machinery is often dysregulated, leading to chromosomal instability and aneuploidy, which contribute to tumor progression and heterogeneity. Key components include the mitotic spindle, cyclins and cyclin-dependent kinases (CDKs), mitotic regulators (e.g., Aurora kinases, Polo-like kinase 1 (PLK1)), and E3 ubiquitin ligase complexes like the Anaphase-Promoting Complex/Cyclosome (APC/C). Defects or dysregulation in components or regulators of the mitotic machinery are common in tumors and are considered promising anticancer drug targets. Many small molecule inhibitors have been developed against CDKs, Aurora kinases, PLK1, and drugs targeting spindle microtubules (e.g., taxanes) disrupt proper spindle formation/function.

Inhibition of mitotic kinases, disruption of spindle microtubule dynamics, inhibition of proteasomal degradation